caa a22 4500 605491550 CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0802-y doi (NATIONALLICENCE)springer-10.1007/s10147-015-0802-y Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis [Elektronische Daten] [Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa] Background: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) in high-risk Pca patients treated with a neoadjuvant therapy comprising a luteinizing-hormone-releasing hormone (LHRH) agonist plus low dose estramustine phosphate (EMP) (LHRH+EMP) followed by radical prostatectomy (RP). In the present study, we used a retrospective design via propensity score matching to elucidate the clinical benefit of neoadjuvant LHRH+EMP for high-risk Pca. Methods: The Michinoku Urological Cancer Study Group database contained data for 1,268 consecutive Pca patients treated with RP alone at 4 institutions between April 2000 and March 2011 (RP alone group). In the RP alone group, we identified 386 high-risk Pca patients. The neoadjuvant LHRH+EMP group included 274 patients with high-risk Pca treated between September 2005 and November 2013 at Hirosaki University. Neoadjuvant LHRH+EMP therapy included LHRH and EMP administration at a dose of 280mg/day for 6months before RP. The outcome measures were overall survival (OS) and BRFS. Results: The propensity score-matched analysis indicated 210 matched pairs from both groups. The 5-year BRFS rates were 90.4 and 65.8% for the neoadjuvant LHRH+EMP and RP alone groups, respectively (P<0.0001). The 5-year OS rates were 100 and 96.1% for the neoadjuvant LHRH+EMP and RP alone groups, respectively (P=0.110). Conclusions: Although the present study was not randomized, neoadjuvant LHRH+EMP therapy followed by RP appeared to reduce the risk of biochemical recurrence. A prospective randomized study is warranted to determine the clinical implications of the neoadjuvant therapy described here. Japan Society of Clinical Oncology, 2015 High-risk prostate cancer nationallicence Prostatectomy nationallicence Neoadjuvant therapy nationallicence LHRH plus estramustine nationallicence Propensity score analysis nationallicence Koie Takuya Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Mitsuzuka Koji Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Yoneyama Takahiro Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Narita Shintaro Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut Kawamura Sadafumi Department of Urology, Miyagi Cancer Center, Natori, Japan aut Kaiho Yasuhiro Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Tsuchiya Norihiko Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut Tochigi Tatsuo Department of Urology, Miyagi Cancer Center, Natori, Japan aut Habuchi Tomonori Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut Arai Yoichi Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Ohyama Chikara Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Yoneyama Tohru Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Tobisawa Yuki Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 1018-1025 1341-9625 20:5<1018 2015 20 10147 https://doi.org/10.1007/s10147-015-0802-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0802-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Koie Takuya Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Mitsuzuka Koji Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Yoneyama Takahiro Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Narita Shintaro Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut NATIONALLICENCE 700 1- Kawamura Sadafumi Department of Urology, Miyagi Cancer Center, Natori, Japan aut NATIONALLICENCE 700 1- Kaiho Yasuhiro Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Tsuchiya Norihiko Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut NATIONALLICENCE 700 1- Tochigi Tatsuo Department of Urology, Miyagi Cancer Center, Natori, Japan aut NATIONALLICENCE 700 1- Habuchi Tomonori Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut NATIONALLICENCE 700 1- Arai Yoichi Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Ohyama Chikara Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Yoneyama Tohru Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Tobisawa Yuki Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 1018-1025 1341-9625 20:5<1018 2015 20 10147